Clinical evaluation of low dose glucocorticoid therapy for hormone- refractory prostate cancer

Japanese Journal of Urology

Volumn 91, Issue 4, 2000, Pages 479-484

  Kobayashi, Tatsuya ^a   Jo, Yoshimasa ^a   Ikegami, Motoyasu ^a   Furukawa, Yoji ^a   Morioka, Masaaki ^a   Tanaka, Hiroyoshi ^a   Kinugawa, Keigo ^b   Ohta, Syuhei ^c  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Department of Urology   (Japan)

^c Kousei General Hospital   (Japan)

Author keywords

Hormone refractory; Low dose glucocorticoid therapy; Prostate cancer

Indexed keywords

ANDROGEN; DEXAMETHASONE; ESTRAMUSTINE; GLUCOCORTICOID; GONADORELIN DERIVATIVE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BONE PAIN; BONE SCINTISCANNING; CLINICAL ARTICLE; HORMONE RESISTANCE; HUMAN; MALE; ORCHIECTOMY; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034108898     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol1989.91.479     Document Type: Article

References (14)

1. Hahn, E.A., Webster, K.A., Cella, D. and Fairclough. D.L. : Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials. Stat-Med. 17(5-7) : 547-549, 1998 Mar15-Apr 15.
2. Huggins, C. and Hodges, C.V. : Studies on prostatic cancer The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1. 293-297, 1941.
3. Huggins, C. and Scott, W.W. : Bilateral adrenalectomy in prostate cancer . clinical features and urinary exdretion of 17-kerosteroids and estrogens. Ann Surg, 122, 1031-1041, 1945.
4. Williams, G., Asopa, R., Abel, P.D. and Smith, C. : Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer. Br. J. Urol., 65, 504-508, 1990.
5. Miller, G.M. and Hinman, F Jr. : Cortisone treatment in advanced carcinoma of the prostate. J. Urol., 72, 485-496, 1954.
6. J) prostate cancer: refining the concept. Urology, 46, 142-148, 1995.
7. Harland, S.J. and Duchesne, G.M : Suramin and prostate cancer : the role of hydrocortisone. Eur. J. Cancer, 28A, 1295, 1992.
8. Stolie, J.A., Buckner, J.C., Wiseman, G.A. Burch, P. A., Hartmann, L.C. and Richardson, R.I. : Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer, 76, 96-100, 1995.
9. Nishiyama, T. and Terunuma, M. : Hormone / anti-hormoe withdrawal and dexamethasone for hormone-refractory prostate cancer. Int. J. Urol., 5, 44-47, 1998.
10. Smith, R.G., Syms, A.J., Nag, A., Lerner, S. and Norris, S. : Mechanism of the glucocorticoid regulation of growth of the androgen-sesitive prostate-derived R 3327 H-G8-A 1 tumor cell line. J. Biol. Chem., 260, 12454-12463, 1985.
11. Tannock, I., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L. and Rider, L. : Treatment of metastatic prostatic cancer with low-dose predonine : evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol., 7, 590-597, 1989
12. Patal, S.R . Kvols, L.K., Hahn, R.G., Windschitl, H., Levitt, R. and Therneau, T. : A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer, 66, 655-658, 1990.